Biosynex SA represents strong values and a clear corporate philosophy. The company's main focus is on providing innovative and reliable diagnostic solutions to improve patient care. Biosynex SA's values include integrity, excellence, and collaboration, aiming to deliver high-quality and accurate diagnostic tests. The company is committed to sustainability, ensuring that its operations are environmentally responsible. With a customer-centric approach, Biosynex SA strives to meet the evolving needs of healthcare professionals and patients. Through continuous innovation and a strong commitment to quality, Biosynex SA aims to make a positive impact in the field of medical diagnostics.

Biosynex SA is primarily present in various countries and regions worldwide. The company operates in several European countries, including France, Germany, Italy, Spain, and the United Kingdom. In addition, Biosynex SA has a presence in other regions such as North America, Africa, and Asia. With its diverse portfolio of innovative medical diagnostic solutions, Biosynex SA has expanded its market reach to serve healthcare professionals and patients globally.

Biosynex SA has achieved several significant milestones throughout its journey. The company has made substantial advancements in the field of diagnostic testing by developing innovative and reliable solutions. Biosynex SA has successfully initiated strategic partnerships and collaborations, expanding its global presence. Moreover, the company has gained regulatory approvals and certifications, ensuring the quality and safety of its products. With a commitment to continuous research and development, Biosynex SA has consistently introduced cutting-edge technologies to enhance healthcare outcomes. These milestones reflect Biosynex SA's dedication to providing breakthrough diagnostic solutions, positioning the company as a leader in the industry.

Biosynex SA is a prominent company specializing in the field of medical diagnostics. Established in 2005, Biosynex has emerged as a leading player in the global healthcare industry. The company focuses on developing and manufacturing innovative diagnostic solutions, including rapid tests, for a wide range of medical conditions. With a strong commitment to research and development, Biosynex has achieved significant milestones in the diagnosis of various diseases, such as infectious diseases, women’s health, and cardiovascular disorders. Through strategic collaborations and a customer-centered approach, Biosynex SA continues to revolutionize the medical diagnostics landscape, ensuring accurate and efficient testing for patients worldwide.

The main competitors of Biosynex SA in the market include (insert competitors' names). The company operates in a highly competitive industry, and these competitors pose a challenge in terms of market share and product offerings. Biosynex SA has been consistently striving to differentiate itself through innovative products, strong marketing strategies, and extensive market presence. Despite the competitive landscape, Biosynex SA has successfully maintained its position and continues to expand its customer base through its commitment to quality, customer satisfaction, and continuous improvement.

Biosynex SA is primarily active in the healthcare industry.

The business model of Biosynex SA revolves around the development, manufacturing, and distribution of rapid diagnostic tests (RDTs) for various medical conditions. Biosynex SA focuses on providing innovative and user-friendly diagnostic solutions that offer fast and reliable results. By leveraging cutting-edge technology and scientific expertise, Biosynex SA aims to improve the accessibility and efficiency of medical testing procedures. Their wide range of rapid diagnostic tests covers areas such as infectious diseases, women's health, gastroenterology, and cardiovascular conditions. Biosynex SA strives to contribute to better healthcare outcomes by offering accurate and time-sensitive diagnostic tools to healthcare professionals and patients alike.

De Biosynex K/W is 51,24.

De Biosynex KUV is 0,36.

De AlleAktien Kwaliteitsscore voor Biosynex is 4/10.

De verwachte Biosynex omzet is 127,31 mln. EUR.

De verwachte Biosynex winst is 886.698,10 EUR.

Biosynex SA is a French company based in Strasbourg that specializes in the development, production, and marketing of rapid tests and other diagnostic solutions. The company was founded in 2005 and has since built up a wide portfolio of products that can be used in various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. The business model of Biosynex SA is based on the manufacture and sale of rapid and easy diagnostic tests that can be used by medical professionals and end consumers. The company offers a wide range of diagnostic solutions, from pregnancy tests to tests for infectious diseases such as HIV, hepatitis B and C, as well as tests for cardiovascular diseases and drug abuse. An important sector of Biosynex SA is the healthcare sector. Here, the company offers various tests that can help detect diseases early and provide a quick diagnosis. These include tests for cholesterol, blood sugar, blood pressure, and other indicators of cardiovascular diseases. In addition, Biosynex SA also offers tests for body fluids such as urine and stool, which can help detect diseases such as urinary tract infections or colorectal cancer early. Another important area of Biosynex SA is the pregnancy sector. Here, the company offers fast and reliable tests that can usually be performed at home. Products in this category include pregnancy tests and ovulation tests, which can help women identify their fertile days and plan for pregnancy. Another important area of Biosynex SA is the sexually transmitted diseases sector. Here, the company offers tests for a variety of infectious diseases, including HIV, hepatitis B and C, chlamydia, and gonorrhea. These tests are easy to perform and can help detect and treat infections early. In addition to these important product categories, Biosynex SA also offers a range of diagnostic solutions that can be used in various medical fields. These include tests for drug abuse, respiratory diseases, anemia, and more. The business model of Biosynex SA is based on the production and sale of fast and reliable diagnostic tests that can be used in various medical fields. The company aims to expand its product range through continuous research and development and to create innovations that can help improve patients' lives and enhance the quality of medical care. The answer is: Biosynex SA is a French company specializing in the development and production of rapid tests and diagnostic solutions for various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. They offer a wide range of tests for different medical needs and aim to improve patients' lives through research and development.

Biosynex keert een dividend van 2,00 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Biosynex of het bedrijf keert geen dividend uit.

De ISIN van Biosynex is FR0011005933.

Het WKN van Biosynex is A1H8G1.

De ticker van Biosynex is ALBIO.PA.

Binnen de laatste 12 maanden betaalde Biosynex een dividend van 2,00 EUR . Dit komt overeen met een dividendrendement van ongeveer 45,98 %. Voor de komende 12 maanden zal Biosynex naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Biosynex is momenteel 45,98 %.

Biosynex betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Biosynex betaalde de afgelopen 2 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Biosynex wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Biosynex van 18-5-2022 ter hoogte van 2 EUR te ontvangen, moest je het aandeel voor de ex-datum op 16-5-2022 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 18-5-2022.

In het jaar 2023 heeft Biosynex 2 EUR aan dividenden uitgekeerd.

De dividenden van Biosynex worden in EUR uitgekeerd.